Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7400 3347

Website: roivant.com

Address:

50 Broadway, 7th Floor, London, United Kingdom

PatBull6912 Jun. 26 at 5:06 AM

$ROIV SCHEDULING ORDER: A Jury Trial is set for 3/9/2026 before Judge Mitchell S. Goldberg. Signed by Judge Mitchell S. Goldberg on 06/25/205. (oam) (Entered: 06/25/2025)

0 · Reply

History101 Jun. 25 at 8:53 PM

$IMVT I assume $ROIV still owns ~ 64% of IMVT, if anyone knows any different plz let us know, thanks

0 · Reply

brs555 Jun. 25 at 8:10 PM

$ROIV $ABUS https://x.com/Roivant/status/1937919957800542284

0 · Reply

renoH4 Jun. 25 at 3:43 PM

$ROIV has ca. 20 % on Arbutus - if Arbutus who actually makes a strategic decision sells his Hepatitis package and gets may be 6 Billions, Roiv makes 1,2 Billion $

0 · Reply

EricKuoTW Jun. 25 at 3:39 PM

$ROIV Is it possible to break through 12 in the near future?

0 · Reply

DonCorleone77 Jun. 25 at 11:48 AM

$ROIV Roivant Sciences announces $500M share repurchase program In a regulatory filing, the company stated, "On June 24, 2025, the board of directors of Roivant Sciences authorized a common share repurchase program allowing for repurchases of the company's common shares in an aggregate amount of up to $500 million. This new authorization is in addition to the $1.5 billion common share repurchase program announced in April 2024, which had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted." cc: @RonIsWrong

1 · Reply

QuiverQuant Jun. 23 at 4:08 PM

Insider Sale: 10% owner at $ROIV Sells 565,266 Shares Read more on $ROIV: https://www.quiverquant.com/news/Insider+Sale%3A+10%25+owner+at+%24ROIV+Sells+565%2C266+Shares

0 · Reply

renoH4 Jun. 18 at 2:01 PM

$ROIV ..added yesterday - this will run fast now - imo

0 · Reply

JarvisFlow Jun. 18 at 11:30 AM

HC Wainwright & Co. has updated their rating for Roivant Sciences ( $ROIV ) to Buy with a price target of 18.

0 · Reply

DonCorleone77 Jun. 16 at 11:14 AM

$ROIV Pulmovant announces publication of PK, lung deposition data for mosliciguat Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetics, PK, in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension. T he peer-reviewed manuscript titled, "Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat: Results from Randomized Phase I Studies in Healthy Men," was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients. cc: @RonIsWrong

0 · Reply

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 18 days ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 4 weeks ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 4 weeks ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 6 weeks ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 2 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 2 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 3 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 3 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 4 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 4 months ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 4 months ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 5 months ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 5 months ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 5 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 5 months ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 7 months ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 7 months ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 8 months ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 8 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 8 months ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 10 months ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 10 months ago

Roivant Flips a Skin Drug to Organon

OGN

Sep 18, 2024, 7:30 AM EDT - 10 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Sep 10, 2024, 6:30 AM EDT - 10 months ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 10 months ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 9, 2024, 12:54 PM EDT - 10 months ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Sep 9, 2024, 7:00 AM EDT - 10 months ago

Roivant Provides Update on Graves' Disease Development Program

Aug 30, 2024, 8:00 AM EDT - 10 months ago

Top Stocks Near Their 200-Day SMA

CCL CUK SM

Aug 22, 2024, 1:00 AM EDT - 11 months ago

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Aug 9, 2024, 12:03 PM EDT - 11 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 2, 2024, 7:27 AM EDT - 1 year ago

Roivant Sciences: Executing On Huge Buyback Program With More To Come

May 30, 2024, 12:23 PM EDT - 1 year ago

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 16, 2024, 4:05 PM EDT - 1 year ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Apr 2, 2024, 7:28 AM EDT - 1 year ago

Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Mar 18, 2024, 3:52 PM EDT - 1 year ago

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Feb 13, 2024, 12:02 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript

Feb 13, 2024, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

Jan 7, 2024, 1:15 PM EST - 1 year ago

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy

Dec 20, 2023, 4:30 PM EST - 1 year ago

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 9:00 AM EST - 1 year ago

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Nov 27, 2023, 8:52 AM EST - 1 year ago

Roivant Sciences shares drop as lupus treatment misses trial goal

Nov 27, 2023, 8:49 AM EST - 1 year ago

Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

Nov 13, 2023, 7:19 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Oct 30, 2023, 5:30 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

PatBull6912 Jun. 26 at 5:06 AM

$ROIV SCHEDULING ORDER: A Jury Trial is set for 3/9/2026 before Judge Mitchell S. Goldberg. Signed by Judge Mitchell S. Goldberg on 06/25/205. (oam) (Entered: 06/25/2025)

0 · Reply

History101 Jun. 25 at 8:53 PM

$IMVT I assume $ROIV still owns ~ 64% of IMVT, if anyone knows any different plz let us know, thanks

0 · Reply

brs555 Jun. 25 at 8:10 PM

$ROIV $ABUS https://x.com/Roivant/status/1937919957800542284

0 · Reply

renoH4 Jun. 25 at 3:43 PM

$ROIV has ca. 20 % on Arbutus - if Arbutus who actually makes a strategic decision sells his Hepatitis package and gets may be 6 Billions, Roiv makes 1,2 Billion $

0 · Reply

EricKuoTW Jun. 25 at 3:39 PM

$ROIV Is it possible to break through 12 in the near future?

0 · Reply

DonCorleone77 Jun. 25 at 11:48 AM

1 · Reply

QuiverQuant Jun. 23 at 4:08 PM

Insider Sale: 10% owner at $ROIV Sells 565,266 Shares Read more on $ROIV: https://www.quiverquant.com/news/Insider+Sale%3A+10%25+owner+at+%24ROIV+Sells+565%2C266+Shares

0 · Reply

renoH4 Jun. 18 at 2:01 PM

$ROIV ..added yesterday - this will run fast now - imo

0 · Reply

JarvisFlow Jun. 18 at 11:30 AM

HC Wainwright & Co. has updated their rating for Roivant Sciences ( $ROIV ) to Buy with a price target of 18.

0 · Reply

DonCorleone77 Jun. 16 at 11:14 AM

0 · Reply

DDRPOWER Jun. 12 at 12:17 AM

$ABUS $ROIV ‘s rapid hostile takeover was deliberate, and its true purpose remains to be seen 👀.

2 · Reply

renoH4 Jun. 11 at 1:55 PM

$ROIV ...$$$ on Monday ;-)

0 · Reply

renoH4 Jun. 10 at 2:13 PM

$ROIV 🎈😀🎈

0 · Reply

lakeswim951 Jun. 3 at 12:26 AM

$ROIV It’s interesting to see 35k 15c Jan 26 open. Wonder if people are writing covered calls knowing the price is so range bound.

0 · Reply

StrategicStockSniper May. 31 at 5:27 PM

Watch this before monday ⬇️🚨 The obesity / Weight loss theme/trend will change lives. This Trend Is Just Starting. $ARWR, $ROIV, $NVOS, $RPHM https://www.tiktok.com/@strategicstocksniper/video/7510661709116394798?is_from_webapp=1&sender_device=pc&web_id=7508604446427924010

0 · Reply

Shortsales May. 29 at 10:22 PM

$ROIV 😏

0 · Reply

DonCorleone77 May. 29 at 11:06 AM

$ROIV Roivant Sciences reports Q4 EPS (29c), consensus (16c) Reports Q4 revenue $7.57M vs $9M last year. "I am incredibly proud of the progress we reported in the final quarter of this past fiscal year. Continued broad development of brepocitinib, positive data from our myasthenia gravis study, and expansion of IMVT-1402 into new indications underscore our commitment to patients. We remain focused on building value in our late-stage clinical pipeline, and on continued discipline on capital allocation across the portfolio," said Matt Gline, CEO of Roivant. "We look forward to a number of exciting milestones later this year, including the upcoming brepocitinib readout in DM." cc: @RonIsWrong

0 · Reply

StockBraker May. 29 at 11:03 AM

$ROIV https://investor.roivant.com/news-releases/news-release-details/roivant-reports-financial-results-fourth-quarter-and-fiscal-1

1 · Reply

ChartBandit02 May. 29 at 10:31 AM

$ROIV is this bull or bear ?????????????????

0 · Reply

renoH4 May. 28 at 1:40 PM

$ROIV ..if we see a settlement between Arbutus and...... the share will make minimum 20 % on one day

1 · Reply

JarvisFlow May. 28 at 11:00 AM

HC Wainwright & Co. has updated their rating for Roivant Sciences ( $ROIV ) to Buy with a price target of 18.

0 · Reply

renoH4 May. 16 at 12:58 PM

$ROIV --is a settlement with Moderna around the corner ?

3 · Reply

Market Cap	7.89B
Revenue (ttm)	29.05M
Net Income (ttm)	-171.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-592.01%
Debt to Equity Ratio	0.00

Volume	11,126,699
Avg Vol	5,990,510
Day's Range	N/A - N/A
Shares Out	679.81M
Stochastic %K	54%
Beta	1.16
Analysts	Strong Sell
Price Target	$16.75